//]]>

High-Risk IV Medications in Special Patient Populations (Record no. 19065)

000 -LEADER
fixed length control field 04524nam a22004935i 4500
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20140310150638.0
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field cr nn 008mamaa
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 110627s2011 xxk| s |||| 0|eng d
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9780857296061
978-0-85729-606-1
050 #4 - LIBRARY OF CONGRESS CALL NUMBER
Classification number RC86-88.9
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number 616.028
Edition number 23
264 #1 -
-- London :
-- Springer London :
-- Imprint: Springer,
-- 2011.
912 ## -
-- ZDB-2-SME
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Kane-Gill, Sandra.
Relator term editor.
245 10 - IMMEDIATE SOURCE OF ACQUISITION NOTE
Title High-Risk IV Medications in Special Patient Populations
Medium [electronic resource] /
Statement of responsibility, etc edited by Sandra Kane-Gill, Joseph Dasta.
300 ## - PHYSICAL DESCRIPTION
Extent X, 160p. 3 illus., 2 illus. in color.
Other physical details online resource.
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note Anesthetic agents (general, inhaled, intravenous) -- Propofol, ketamine, etc -- Anti-infectives -- aminoglycosides, vancomycin, drotrecogin, amphotericin products -- inhaled agents -- Anticoagulants agents -- unfractionated heparin, low molecular weight heparins, fondaparinux, lepirudin, argatroban, bivalrudin, abciximab, eptifibatide, tirofiban -- Thrombolytics –reteplase, tenecteplase, streptokinase, urokinase, alteplase -- Cardiac Drugs -- Adrenergic agents -- dopamine, dobutamine, vasopressin, , nitroglycerin, nitroprusside epinephrine, norepinepherine, phenylepherine -- Adrenergic antagonists -- Propranolol, diltiazem, verapamil, esmolol, labetalol, clevidipine -- Antidyrrhthmics -- amiodarone, lidocaine, procainamide -- Inotropic agents -- milrinone, amrinone, isoproterenol, niseritide, digoxin -- Prostanoids -- Epoprostenol, iloprost, treprostenil -- Electrolytes -- Potassium, magnesium, sodium chloride (hypertonic), cardioplegic solutions -- Hypoglycemics -- Insulin and oral agents -- Neuromuscular blocking agents -- vecuronium, rocuronium, cisatracurium, atracurium, succinylcholine -- Opioids (IV, oral) -- Remifentanyl, fentanyl , morphine, hydromorphone, meperidine -- Sedatives (IV, oral and transdermal) -- lorazepam, midazolam, diazepam, propofol, dexmedetomidine -- Information for Each Drug -- Propofol -- Normal -- Obese -- Renal Dysfunction -- CrCL -- Dialysis (HD, CRRT) -- Liver Dysfunction -- Recommendations for Safe Use.
520 ## - SUMMARY, ETC.
Summary, etc Critically ill patients are at risk for a higher frequency and severity of adverse drug events (ADEs), and special patient populations of the critically ill – requiring for instance individualized dosing due to non-average weight, hepatic or renal dysfunction, extracorporeal circulation devices, advanced age, pharmacogenetic alterations, hemodynamic instability, or therapeutic hypothermia – are particularly challenging. A contributing factor to this is the use of high-risk medications with many administered intravenously (IV). Hypervigilant monitoring of high-risk medications is still essential to prevent patient harm, especially in populations that have dosing challenges, hence, regulatory bodies internationally require active institutional surveillance of high-risk medications. These dosing challenges are a great safety concern, since there is considerable risk of unwanted adverse drug events from overdosing or therapeutic inefficacy from underdosing. High-Risk IV Medications in Special Patient Populations reviews high-risk IV medication dosage considerations for special patient populations and discusses the safety concerns of these medications to aid the clinician in cautious monitoring.  The authors provide clinicians with tools to minimize adverse drug events with IV high-risk medications, while maximizing the beneficial clinical effects of these drugs, thus making this book essential reading for all involved with the care of critically ill patients. 
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Medicine.
Topical term or geographic name as entry element Pharmacy.
Topical term or geographic name as entry element Anesthesiology.
Topical term or geographic name as entry element Emergency medicine.
Topical term or geographic name as entry element Critical care medicine.
Topical term or geographic name as entry element Internal medicine.
Topical term or geographic name as entry element Medicine & Public Health.
Topical term or geographic name as entry element Intensive / Critical Care Medicine.
Topical term or geographic name as entry element Internal Medicine.
Topical term or geographic name as entry element Emergency Medicine.
Topical term or geographic name as entry element Anesthesiology.
Topical term or geographic name as entry element Pharmacy.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Dasta, Joseph.
Relator term editor.
710 2# - ADDED ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element SpringerLink (Online service)
773 0# - HOST ITEM ENTRY
Title Springer eBooks
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Display text Printed edition:
International Standard Book Number 9780857296054
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier http://dx.doi.org/10.1007/978-0-85729-606-1
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme
Item type E-Book
Copies
Price effective from Permanent location Date last seen Not for loan Date acquired Source of classification or shelving scheme Koha item type Damaged status Lost status Withdrawn status Current location Full call number
2014-04-03AUM Main Library2014-04-03 2014-04-03 E-Book   AUM Main Library616.028
Languages: 
English |
العربية